HC Wainwright & Co. initiated coverage on Biophytis with a new price target
$BPTS
Biotechnology: Pharmaceutical Preparations
Health Care
HC Wainwright & Co. initiated coverage of Biophytis with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/25/2021 | $15.00 | Buy | HC Wainwright & Co. |
6-K - Biophytis SA (0001768946) (Filer)
6-K - Biophytis SA (0001768946) (Filer)
6-K - Biophytis SA (0001768946) (Filer)
IND to be filed with the FDA in the coming weeksPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity.This Scientific Advisory Board will be composed of a few worldwide medical experts in the field of obesity, including Professor Dennis Villareal from the USA and Professor Francisco Guarner from Spain. The OBA SAB will guide the company to develop BIO101 (20-hydroxy
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA ((Nasdaq CM:BPTS, PARIS:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced the strengthening of its management team with the appointment of Edouard Bieth as Chief Business Officer and member of the Executive Committee.Stanislas Veillet, Chief Executive Officer of Biophytis, stated: "Over the past two years, Bioph
Appointment of Chiara Baccelli as Director of Pharmaceutical Operations and Quality AssuranceAppointment of Nicolas Fellmann as Chief Financial OfficerPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWORE / May 2, 2023 / Biophytis SA ((NasdaqCM: BPTS, PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, announces today the strengthening of its management team with the appointment of Chiara Baccelli to the newly created position of Director of Pharmaceutical Operations and Quality Assurance an
Success of the placement with professional investors, historical supporters of the Company, for an amount of €1.9M.Strong participation of retail investors via the PrimaryBid platform with an offer allocated to €0.4M[1].Funds raised to finance the Marketing Authorisation Applications of Sarconeos (BIO101) for the treatment of severe forms of COVID-19.PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 11, 2023 / Biophytis SA (NasdaqCM:BPTS)(PARIS:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID
Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug Sarconeos (BIO101) developed by Biophytis in the context of the early access program application.The application request for early access program, currently underway with the Haute Autorité de Santé (the French National Authority for Health, HAS), aims to allow treatment with Sarconeos (BIO101) for hospitalized patients with severe forms of COVID-19 as of the second half of 2023.PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 2, 2023 / Biophytis SA (NASDAQ:BPTS)(PARIS:ALBPS) (the "Company" or "Biop
Biophytis to present the early access application in France at a pre-filing meeting in March with the HASBiophytis plans to file the application shortly after with the objective of obtaining early access authorization in France in the second quarter of 2023Biophytis is pursuing in parallel the preparation of the conditional marketing authorization application due to the health emergency in Europe and the United StatesPARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / February 27, 2023 / Biophytis SA ((NasdaqCM: BPTS, PARIS:ALBPS) (the "Company" or "Biophytis"), a biotechnology company focused on the development of drugs to slow the degenerative processes associated with aging, including severe res
HC Wainwright & Co. initiated coverage of Biophytis with a rating of Buy and set a new price target of $15.00
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Biophytis SA (PARIS:ALBPS) ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on developing treatments for age-related diseases, publishes today its financial results for the first half of 2024 and provides an update on the company's key achievements.Stanislas Veillet, CEO of Biophytis, commented:"We are particularly pleased with the progress made in the first half of 2024. The launch of our clinical program OBA for obesity, addressing a major public health issue, and our partnership with Blanver to develop BIO101 in Latin America, are key milestones that demonstrate Biophytis' ability to innovate
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strategy in Asia.To expand its presence in this strategic region, Biophytis has today signed two contracts with local agents: one for Japan and South Korea, the other for China and Southeast Asia. These agents will leverage their networks within the pharmaceutical sector to support Biophytis in identifying partners for the drug candidate BIO101 (20-hydroxyecdysone) in these different countries.This initiative is
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (PARIS:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announced that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) for its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone).The primary objective of the study is to measure the improvement in muscle strength in the lower limbs, as assessed by knee extension test. Secondary endpoints will include analysis of mobility (via the 6-minute walk test) and body composition (assessment of fat an